Harvard Bioscience Inc
NASDAQ:HBIO
Harvard Bioscience Inc
Cash from Financing Activities
Harvard Bioscience Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Harvard Bioscience Inc
NASDAQ:HBIO
|
Cash from Financing Activities
-$12.1m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Cash from Financing Activities
-$3.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
Danaher Corp
NYSE:DHR
|
Cash from Financing Activities
-$144m
|
CAGR 3-Years
67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
17%
|
|
West Pharmaceutical Services Inc
NYSE:WST
|
Cash from Financing Activities
-$659.6m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
-34%
|
|
Agilent Technologies Inc
NYSE:A
|
Cash from Financing Activities
-$1.2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-8%
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Cash from Financing Activities
-$382m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
See Also
What is Harvard Bioscience Inc's Cash from Financing Activities?
Cash from Financing Activities
-12.1m
USD
Based on the financial report for Dec 31, 2023, Harvard Bioscience Inc's Cash from Financing Activities amounts to -12.1m USD.
What is Harvard Bioscience Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-15%
Over the last year, the Cash from Financing Activities growth was -327%. The average annual Cash from Financing Activities growth rates for Harvard Bioscience Inc have been -15% over the past three years .